Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Pancreatic Neoplasms 68Breast Neoplasms 58Carcinoma, Non-Small-Cell Lung 36Triple Negative Breast Neoplasms 28Squamous Cell Carcinoma of Head and Neck 15Neoplasms 11Head and Neck Neoplasms 11Lung Neoplasms 10Esophageal Squamous Cell Carcinoma 10Neoplasm Metastasis 7Stomach Neoplasms 6Melanoma 6Adenocarcinoma 6Esophageal Neoplasms 5Cholangiocarcinoma 5Advanced Pancreatic Cancer 5Inflammatory Breast Neoplasms 4Gallbladder Neoplasms 4Fallopian Tube Neoplasms 4Carcinoma 4Small Cell Lung Carcinoma 3Recurrence 3Pathologic Complete Response 3Ovarian Neoplasms 3Neoplasms by Site 3Laryngeal Neoplasms 3Hypopharyngeal Neoplasms 3Carcinoma, Squamous Cell 3Uveal Melanoma 2Uterine Cervical Neoplasms 2

Interventions

Gemcitabine 83Cisplatin 59pembrolizumab 28Paclitaxel 21Nivolumab 21Carboplatin 21Cystectomy 20Docetaxel 18durvalumab 17atezolizumab 17Magnetic Resonance Spectroscopy 16Specimen Handling 15Radiotherapy 14avelumab 13Mitomycin 13Sunitinib 12Doxorubicin 12Methotrexate 11Fluorouracil 11Vinblastine 10Filgrastim 7BCG Vaccine 7Sorafenib 6Ipilimumab 6Immunoglobulin G 6Disulfides 6Biopsy 6enfortumab vedotin 5cabozantinib 5Trastuzumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Urinary Bladder Neoplasms × 130-nm albumin-bound paclitaxel × Clear all
NCT02887248 2023-12-05

Nab-paclitaxel Plus Gemcitabine as First-line Therapy for Cisplatin-ineligible or Cisplatin-incurable Advanced Urothelial Carcinoma

SCRI Development Innovations, LLC

Phase 2 Terminated
3 enrolled 9 charts
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡